The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

HHS Secretary Robert F. Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the ...

The health system has rolled out AssistIQ, an AI-powered computer vision platform at North Shore… The FDA has approved expanded use of Sanofi Pasteur’s MenQuadfi, a meningococcal conjugate ...

Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

On May 23, 2025, the FDA expanded the approval of MenQuadfi (Sanofi) to include infants aged 6 weeks to 23 months for the prevention of meningococcal disease. MenQuadfi is now the only quadrivalent ...